Il sovraccarico di ferro e la terapia chelante

Translated title of the contribution: Iron overload and chelation therapy

G. Fiorelli, L. Ciceri, M. D. Cappellini, S. Fargion

Research output: Contribution to journalArticle

Abstract

Clinical evidence for heart, liver and endocrine toxicity due to iron has been provided by studies of patients with genetic hemochromatosis (GH) and secondary hemochromatosis due to beta-thalassemia or to other chronic transfusion dependent anemias. Direct measurement of hepatic iron concentrations is the most sensitive method for determining the body iron burden. Phlebotomy is the choice treatment in primary iron overload (GH): 500 ml of blood removed contain about 200 mg of iron; it should be possible to remove up to 20 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of chilating agent desferrioxamine (DFO) results in mobilization and urinary excretion of up to 20 mg of iron/day. In beta-thalassemia patients. During treatment with DFO, significant reduction in liver iron concentration with little change in hepatic fibrosis were seen. Recently an oral iron chelator Deferiprone (L1) has been used in a group of patients with thalassemia major. The results demonstrate good efficacy in a short-term treatment; the toxicity is under evaluation.

Original languageItalian
Pages (from-to)251-264
Number of pages14
JournalArgomenti di Gastroenterologia Clinica
Volume10
Issue number6
Publication statusPublished - 1997

Fingerprint

Chelation Therapy
Iron Overload
Iron
Hemochromatosis
beta-Thalassemia
Subcutaneous Infusions
Deferoxamine
Liver
Intramuscular Injections
Body Burden
Phlebotomy
Chelating Agents
Anemia
Fibrosis
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Il sovraccarico di ferro e la terapia chelante. / Fiorelli, G.; Ciceri, L.; Cappellini, M. D.; Fargion, S.

In: Argomenti di Gastroenterologia Clinica, Vol. 10, No. 6, 1997, p. 251-264.

Research output: Contribution to journalArticle

@article{5224232a23d145f4b88832005730dbaf,
title = "Il sovraccarico di ferro e la terapia chelante",
abstract = "Clinical evidence for heart, liver and endocrine toxicity due to iron has been provided by studies of patients with genetic hemochromatosis (GH) and secondary hemochromatosis due to beta-thalassemia or to other chronic transfusion dependent anemias. Direct measurement of hepatic iron concentrations is the most sensitive method for determining the body iron burden. Phlebotomy is the choice treatment in primary iron overload (GH): 500 ml of blood removed contain about 200 mg of iron; it should be possible to remove up to 20 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of chilating agent desferrioxamine (DFO) results in mobilization and urinary excretion of up to 20 mg of iron/day. In beta-thalassemia patients. During treatment with DFO, significant reduction in liver iron concentration with little change in hepatic fibrosis were seen. Recently an oral iron chelator Deferiprone (L1) has been used in a group of patients with thalassemia major. The results demonstrate good efficacy in a short-term treatment; the toxicity is under evaluation.",
author = "G. Fiorelli and L. Ciceri and Cappellini, {M. D.} and S. Fargion",
year = "1997",
language = "Italian",
volume = "10",
pages = "251--264",
journal = "Argomenti di Gastroenterologia Clinica",
issn = "1120-8651",
publisher = "Masson SpA",
number = "6",

}

TY - JOUR

T1 - Il sovraccarico di ferro e la terapia chelante

AU - Fiorelli, G.

AU - Ciceri, L.

AU - Cappellini, M. D.

AU - Fargion, S.

PY - 1997

Y1 - 1997

N2 - Clinical evidence for heart, liver and endocrine toxicity due to iron has been provided by studies of patients with genetic hemochromatosis (GH) and secondary hemochromatosis due to beta-thalassemia or to other chronic transfusion dependent anemias. Direct measurement of hepatic iron concentrations is the most sensitive method for determining the body iron burden. Phlebotomy is the choice treatment in primary iron overload (GH): 500 ml of blood removed contain about 200 mg of iron; it should be possible to remove up to 20 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of chilating agent desferrioxamine (DFO) results in mobilization and urinary excretion of up to 20 mg of iron/day. In beta-thalassemia patients. During treatment with DFO, significant reduction in liver iron concentration with little change in hepatic fibrosis were seen. Recently an oral iron chelator Deferiprone (L1) has been used in a group of patients with thalassemia major. The results demonstrate good efficacy in a short-term treatment; the toxicity is under evaluation.

AB - Clinical evidence for heart, liver and endocrine toxicity due to iron has been provided by studies of patients with genetic hemochromatosis (GH) and secondary hemochromatosis due to beta-thalassemia or to other chronic transfusion dependent anemias. Direct measurement of hepatic iron concentrations is the most sensitive method for determining the body iron burden. Phlebotomy is the choice treatment in primary iron overload (GH): 500 ml of blood removed contain about 200 mg of iron; it should be possible to remove up to 20 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of iron in a single year. Daily intramuscular injection or subcutaneous infusion of 0.5 to 1.0 g of chilating agent desferrioxamine (DFO) results in mobilization and urinary excretion of up to 20 mg of iron/day. In beta-thalassemia patients. During treatment with DFO, significant reduction in liver iron concentration with little change in hepatic fibrosis were seen. Recently an oral iron chelator Deferiprone (L1) has been used in a group of patients with thalassemia major. The results demonstrate good efficacy in a short-term treatment; the toxicity is under evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0031414410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031414410&partnerID=8YFLogxK

M3 - Articolo

VL - 10

SP - 251

EP - 264

JO - Argomenti di Gastroenterologia Clinica

JF - Argomenti di Gastroenterologia Clinica

SN - 1120-8651

IS - 6

ER -